Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM Biologics and Crucell have entered a PER.C6 licensing agreement with Japan-based Daiichi Sankyo for the PER.C6 cell line.
Subscribe to our email newsletter
<p>The license agreement allows Daiichi Sankyo to use the PER.C6 cell line in its early stage research to identify new antibodies and for the production of preclinical grade material. <br /><br />The PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies.<br /><br /><br /></p>